X
Search Filters
Format Format
Format Format
X
Sort by Item Count (A-Z)
Filter by Count
Journal Article (2747) 2747
Newsletter (15) 15
Newspaper Article (13) 13
Book Chapter (9) 9
Magazine Article (3) 3
Conference Proceeding (2) 2
Dissertation (1) 1
Transcript (1) 1
more...
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
rivaroxaban (2323) 2323
humans (2253) 2253
anticoagulants (1237) 1237
dabigatran (1178) 1178
anticoagulants - adverse effects (1173) 1173
warfarin (1113) 1113
male (1018) 1018
female (994) 994
administration, oral (925) 925
anticoagulants - therapeutic use (875) 875
aged (873) 873
apixaban (789) 789
anticoagulants - administration & dosage (773) 773
atrial fibrillation (736) 736
hemorrhage - chemically induced (719) 719
middle aged (697) 697
venous thromboembolism (622) 622
stroke (618) 618
treatment outcome (614) 614
prevention (609) 609
thromboembolism (588) 588
atrial fibrillation - drug therapy (587) 587
risk factors (555) 555
rivaroxaban - adverse effects (530) 530
cardiac & cardiovascular systems (516) 516
hematology (514) 514
stroke - prevention & control (476) 476
peripheral vascular disease (462) 462
aged, 80 and over (424) 424
pharmacology & pharmacy (423) 423
safety (408) 408
atrial fibrillation - complications (404) 404
morpholines - adverse effects (400) 400
thiophenes - adverse effects (399) 399
factor xa inhibitors - adverse effects (398) 398
atrial-fibrillation (390) 390
rivaroxaban - therapeutic use (390) 390
morpholines - therapeutic use (376) 376
thiophenes - therapeutic use (376) 376
risk (366) 366
bleeding (364) 364
warfarin - adverse effects (361) 361
rivaroxaban - administration & dosage (345) 345
abridged index medicus (334) 334
thrombosis (333) 333
pyrazoles - adverse effects (325) 325
pyridones - adverse effects (324) 324
medicine, general & internal (323) 323
management (320) 320
adult (314) 314
dabigatran etexilate (310) 310
pyrazoles - therapeutic use (304) 304
pyridones - therapeutic use (303) 303
factor xa inhibitors (302) 302
anticoagulation (295) 295
enoxaparin (293) 293
patients (290) 290
warfarin - therapeutic use (285) 285
analysis (284) 284
cardiac arrhythmia (283) 283
venous thromboembolism - prevention & control (280) 280
drug therapy (279) 279
factor xa inhibitors - therapeutic use (279) 279
oral anticoagulants (275) 275
therapy (274) 274
stroke - etiology (273) 273
morpholines - administration & dosage (271) 271
thiophenes - administration & dosage (271) 271
beta-alanine - analogs & derivatives (267) 267
care and treatment (263) 263
vitamin k - antagonists & inhibitors (262) 262
thromboprophylaxis (258) 258
factor xa inhibitors - administration & dosage (256) 256
pyridones - administration & dosage (255) 255
double-blind (254) 254
pyrazoles - administration & dosage (254) 254
retrospective studies (250) 250
dabigatran - adverse effects (242) 242
venous thromboembolism - drug therapy (242) 242
medicine & public health (241) 241
stroke prevention (241) 241
mortality (238) 238
hemorrhage (235) 235
blood coagulation - drug effects (232) 232
risk assessment (228) 228
clinical trials (227) 227
aspirin (224) 224
edoxaban (224) 224
thrombin (222) 222
dosage and administration (213) 213
pharmacokinetics (213) 213
deep-vein thrombosis (211) 211
surgery (211) 211
warfarin - administration & dosage (207) 207
efficacy (206) 206
cardiology (205) 205
randomized controlled trials as topic (204) 204
benzimidazoles - therapeutic use (189) 189
time factors (188) 188
factor-xa inhibitor (187) 187
more...
Language Language
Language Language
X
Sort by Item Count (A-Z)
Filter by Count
English (2613) 2613
German (73) 73
French (32) 32
Russian (24) 24
Spanish (15) 15
Japanese (13) 13
Chinese (8) 8
Polish (5) 5
Czech (4) 4
Hungarian (4) 4
Italian (4) 4
Norwegian (3) 3
Swedish (3) 3
Danish (2) 2
Dutch (2) 2
Portuguese (2) 2
Turkish (2) 2
Finnish (1) 1
Korean (1) 1
more...
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


The New England journal of medicine, ISSN 1533-4406, 2008, Volume 358, Issue 26, pp. 2765 - 2775
Rivaroxaban is an orally administered direct inhibitor of factor Xa. As compared with enoxaparin, rivaroxaban was more effective in preventing venous... 
ORAL XIMELAGATRAN | MEDICINE, GENERAL & INTERNAL | FACTOR-XA INHIBITOR | KNEE REPLACEMENT | BAY-59-7939 | DEEP-VENOUS THROMBOSIS | MOLECULAR-WEIGHT HEPARIN | MAJOR ORTHOPEDIC-SURGERY | DOUBLE-BLIND | PREVENTION | THROMBOEMBOLISM | Thiophenes - therapeutic use | Pulmonary Embolism - prevention & control | Venous Thromboembolism - mortality | Factor Xa Inhibitors | Thiophenes - adverse effects | Humans | Middle Aged | Male | Enoxaparin - therapeutic use | Pulmonary Embolism - epidemiology | Enoxaparin - adverse effects | Rivaroxaban | Venous Thromboembolism - prevention & control | Aged, 80 and over | Adult | Female | Venous Thrombosis - prevention & control | Morpholines - adverse effects | Morpholines - therapeutic use | Double-Blind Method | Anticoagulants - therapeutic use | Arthroplasty, Replacement, Hip | Anticoagulants - adverse effects | Venous Thrombosis - epidemiology | Adolescent | Aged | Enoxaparin | Dosage and administration | Blood coagulation factors | Comparative analysis | Health aspects | Hip joint | Clinical trials | Comparative studies | Joint surgery | Drug therapy | Clinical outcomes | Blood clots | Index Medicus | Abridged Index Medicus | Enoxaparin/adverse effects/therapeutic use | Venous Thrombosis/epidemiology/prevention & control | Thiophenes/adverse effects/therapeutic use | Arthroplasty | Replacement | Kirurgi | Hip | Morpholines/adverse effects/therapeutic use | 80 and over | Surgery | Anticoagulants/adverse effects/therapeutic use | Venous Thromboembolism/mortality/prevention & control | Factor Xa/antagonists & inhibitors | Pulmonary Embolism/epidemiology/prevention & control
Journal Article
Circulation, ISSN 0009-7322, 07/2016, Volume 134, Issue 3, pp. 248 - 261
.... In addition to familiarity with the dosing and monitoring of vitamin K antagonists, clinicians are accustomed to using vitamin K if there is a need to reverse the anticoagulant effect of vitamin K antagonists... 
anticoagulants | atrial fibrillation | venous thromboembolism | hemorrhage | CARDIAC & CARDIOVASCULAR SYSTEMS | ACTIVATED FACTOR-VII | ATRIAL-FIBRILLATION | IN-VITRO | THROMBIN GENERATION | DABIGATRAN ETEXILATE | PROTHROMBIN COMPLEX CONCENTRATE | SYMPTOMATIC VENOUS THROMBOEMBOLISM | PRACTICAL MANAGEMENT | PERIPHERAL VASCULAR DISEASE | STAGE RENAL-DISEASE | FACTOR XA INHIBITOR | Recombinant Proteins - therapeutic use | Plasma | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Hemorrhage - prevention & control | Recombinant Proteins - adverse effects | Thiazoles - therapeutic use | Factor VIIa - therapeutic use | Arginine - analogs & derivatives | Dabigatran - therapeutic use | Thiazoles - adverse effects | Pyridines - adverse effects | Rivaroxaban - adverse effects | Factor Xa - therapeutic use | Rivaroxaban - therapeutic use | Factor Xa - adverse effects | Pyrazoles - adverse effects | Pyridines - therapeutic use | Antibodies, Monoclonal, Humanized - therapeutic use | Administration, Oral | Antithrombins - therapeutic use | Piperazines - therapeutic use | Dabigatran - antagonists & inhibitors | Piperazines - adverse effects | Factor Xa Inhibitors - therapeutic use | Hemorrhage - drug therapy | Antithrombins - adverse effects | Factor Xa Inhibitors - adverse effects | Blood Coagulation Factors - therapeutic use | Arginine - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Hemostatics - therapeutic use | Arginine - therapeutic use | Pyridones - adverse effects
Journal Article
Clinical orthopaedics and related research, ISSN 1528-1132, 2008, Volume 466, Issue 3, pp. 714 - 721
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2017, Volume 376, Issue 13, pp. 1211 - 1222
Journal Article
International Journal of Cardiology, ISSN 0167-5273, 2014, Volume 179, pp. 279 - 287
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2012, Volume 366, Issue 14, pp. 1287 - 1297
Journal Article
The New England journal of medicine, ISSN 1533-4406, 2016, Volume 375, Issue 12, pp. 1131 - 1141
Journal Article
Cochrane Database of Systematic Reviews, ISSN 1469-493X, 11/2017, Volume 2017, Issue 11, p. CD011373
Background Chronic kidney disease (CKD) is an independent risk factor for atrial fibrillation (AF), which is more prevalent among CKD patients than the general... 
Kidney disease | Anticoagulants | Pyridines | Renal Insufficiency, Chronic | Stroke | Warfarin | Administration, Oral | Pyrazoles | Pyridones | Chronic kidney disease | Dabigatran | Hemorrhage | Embolism | Randomized Controlled Trials as Topic | Arrythmias | Rivaroxaban | Cardiovascular risk management | Antithrombins | Thiazoles | Heart & circulation | General management | Medicine General & Introductory Medical Sciences | Atrial Fibrillation | EAST-ASIAN PATIENTS | MEDICINE, GENERAL & INTERNAL | J-ROCKET AF | XA NEXT-GENERATION | TRANSIENT ISCHEMIC ATTACK | AF-TIMI 48 | VITAMIN-K ANTAGONISM | RIVAROXABAN VS. WARFARIN | LY RANDOMIZED EVALUATION | PERIPHERAL ARTERY-DISEASE | SEVERE RENAL IMPAIRMENT | Dabigatran - adverse effects | Pyrazoles - therapeutic use | Humans | Warfarin - adverse effects | Renal Insufficiency, Chronic - complications | Thiazoles - therapeutic use | Dabigatran - therapeutic use | Thiazoles - adverse effects | Warfarin - therapeutic use | Pyridines - adverse effects | Rivaroxaban - adverse effects | Rivaroxaban - therapeutic use | Pyrazoles - adverse effects | Pyridines - therapeutic use | Stroke - prevention & control | Embolism - prevention & control | Hemorrhage - epidemiology | Antithrombins - therapeutic use | Atrial Fibrillation - complications | Anticoagulants - therapeutic use | Anticoagulants - adverse effects | Antithrombins - adverse effects | Pyridones - therapeutic use | Hemorrhage - chemically induced | Pyridones - adverse effects
Journal Article